Veru Healthcare (NASDAQ: FHCO) Starts Presentation at LD Micro 2017 Invitational
Veru Healthcare (NASDAQ: FHCO) is a medical therapeutics company, develops, manufactures, and markets consumer health care products. The company's pharmaceuticals product portfolio includes the Tamsulosin delayed release sachet that is under bioequivalence study for the treatment of benign prostatic hyperplasia; MSS-722, a fixed ratio of trans- and cis-clomiphene citrate isomers, which is under the phase II clinical trial to treat male infertility caused by testicular dysfunction; APP-944, a zuclomiphene citrate that is under the phase II clinical trial for the treatment of hot flashes in men on prostate cancer hormonal therapies; and APP-111, an oral tubulin targeting chemotherapy, which is…







